Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2014 Oct;20(12):1602-8. doi: 10.1177/1352458514527863. Epub 2014 Mar 12.

Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.

Author information

1
Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain jrio@vhebron.net.
2
Unitat de Ressonància Magnètica (IDI), Servei de Radiologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
3
Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
4
Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain Unitat de Ressonància Magnètica (IDI), Servei de Radiologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Abstract

BACKGROUND:

In patients with relapsing-remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA).

OBJECTIVE:

The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA.

METHODS:

This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables.

RESULTS:

The total possible score range was 0-3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively).

CONCLUSIONS:

In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.

KEYWORDS:

Disability; glatiramer acetate; magnetic resonance imaging; multiple sclerosis; predictive model; relapse; relapsing–remitting multiple sclerosis; risk assessment; treatment response

PMID:
24622350
DOI:
10.1177/1352458514527863
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center